HB-adMSCs is under clinical development by Hope Biosciences and currently in Phase I for Primary Lateral Sclerosis. According to GlobalData, Phase I drugs for Primary Lateral Sclerosis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HB-adMSCs LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HB-adMSCs overview

Cell therapy is under development for the treatment of hip osteoarthritis, traumatic brain injury, cerebral palsy, relapsing remitting multiple sclerosis (RRMS), spinal cord injury (C5-C7 level), LMNA-related congenital muscular dystrophy (L-CMD), multiple sclerosis Parkinson's disease, chronic musculoskeletal pain, coronavirus disease 2019 (COVID-19), amyotrophic lateral sclerosis and primary lateral sclerosis. The drug candidate comprises of autologous adipose derived mesenchymal stem cells. It was also under development for systemic lupus erythematosus (SLE), prostate cancer, glioblastoma multiforme (GBM), rheumatoid arthritis, pancreatic cancer, stroke and Huntington disease and Alzheimer's disease.

Hope Biosciences overview

Hope Biosciences is a biopharmaceutical company that offers mesenchymal stem cell culture products and services for adults and newborns. Hope Biosciences is headquartered in Sugar Land, Texas, the US.

For a complete picture of HB-adMSCs’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.